Changing within the same class: efficacy of brodalumab in plaque psoriasis after treatment with an IL-17A blocker - a retrospective multicenter study.

Kromer, C; Wilsmann-Theis, D; Gerdes, S; Krebs, S; Pinter, A; Philipp, S; Mössner, R

Kromer, C; Wilsmann-Theis, D; Gerdes, S; Krebs, S; Pinter, A; Philipp, S; Mössner, R.

Afiliación

Kromer C; Department of Dermatology, University Medical Center Göttingen, Göttingen, Germany.
Wilsmann-Theis D; Department of Dermatology, University Bonn, Bonn, Germany.
Gerdes S; Psoriasis-Center, Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
Krebs S; Psoriasis-Center, Department of Dermatology, University Hospital Schleswig-Holstein, Kiel, Germany.
Pinter A; Department of Dermatology, Venereology, and Allergology, University Hospital, Frankfurt, Frankfurt/Main, Germany.
Philipp S; Department of Dermatology, Charité Universitätsmedizin Berlin, Berlin, Germany.
Mössner R; Department of Dermatology, University Medical Center Göttingen, Göttingen, Germany.

J Dermatolog Treat ; 32(8): 878-882, 2021 Dec.

Article en En | MEDLINE | ID: mdl-32011917

Asunto(s)

Interleucina-17; Psoriasis; Anticuerpos Monoclonales/efectos adversos; Anticuerpos Monoclonales Humanizados; Humanos; Psoriasis/tratamiento farmacológico; Estudios Retrospectivos; Índice de Severidad de la Enfermedad; Resultado del Tratamiento

Palabras clave

Brodalumab; IL-17 switching; ixekizumab; secukinumab

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google

Texto completo: 1 Colección: 01-internacional Base de datos: MEDLINE Asunto principal: Psoriasis / Interleucina-17 Tipo de estudio: Observational_studies / Prognostic_studies / Risk_factors_studies Límite: Humans Idioma: En Revista: J Dermatolog Treat Asunto de la revista: DERMATOLOGIA Año: 2021 Tipo del documento: Article País de afiliación: Alemania Pais de publicación: Reino Unido

Texto completo

Añadir a Mi BVS

Imprimir

XML

PubMed Links

Buscar en Google